Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  Dassault Systèmes SE    DSY   FR0000130650

DASSAULT SYSTÈMES SE

(DSY)
  Report
SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Dassault Systemes : Medidata Acquires Digital Biomarker Business of MC10, Enhancing Remote Biometric Data Capture Capabilities in Hybrid and Virtual Clinical Trials

10/27/2020 | 12:10pm EST

NEW YORK - October 27, 2020 - Medidata, a Dassault Systèmes company, the global leader in creating end-to-end solutions to support the entire clinical development process, acquired the digital biomarker business of MC10. MC10's offerings will bring novel clinical analytics and biosensor capabilities to Medidata's existing Patient Cloud solutions in ePRO (patient-reported outcomes), eCOA (clinical outcome assessments), and biomarker discovery. This will enhance Medidata's capabilities of integrating data from wearable sensors - including clinical grade metrics - to help customers successfully virtualize clinical trials.

Remote, patient-centered technologies have become an essential part of clinical research, especially in the age of COVID-19; the physical restrictions placed on patients and clinical sites caused by the pandemic can interfere with launching a clinical study and carrying it to completion. Wearable sensors are used in about 15 percent of studies, and the use of sensors is expected to grow to approximately 70 percent by 2025.*

Medidata leads the industry in building and integrating new technologies to revolutionize clinical research in pursuit of patient-centric therapy development. MC10's focus on clinical grade data capture and novel digital biomarker development represent an important next chapter - advancing the understanding of disease progression and treatment effect in the home.

'Medidata is excited to add the pioneering work at MC10 to our ongoing efforts in building a new platform for ingestion and analytics across a wide array of mobile sensors,' said Anthony Costello, senior vice president, Mobile Health, Medidata. 'Incorporating remote biometric data capture and analysis that includes the MC10 nPoint Biostamp, alongside other leading mobile devices, will further strengthen the Medidata platform and help propel the digital transformation of life sciences.'

An integrated Medidata offering will provide research companies and device developers new and innovative ways to collect, normalize and analyze data in pursuit of new therapy development. This enhanced capability will also create a closer connection between patients and the ecosystem of trailblazing researchers, practitioners, and life science companies committed to deepening a shared understanding of disease, transformational therapies, and novel endpoints.

'Medidata is an exceptional fit for MC10. Our combined expertise will help customers and partners take a more data-driven approach to bringing targeted therapies to patients,' said Ben Schlatka, co-founder and CEO, MC10. 'We are looking forward to moving ahead together, accelerating the development and deployment of new innovative offerings for our customers and ultimately transforming therapy development to improve the lives of patients.'

Medidata is a wholly owned subsidiary of Dassault Systèmes, which with its 3DEXPERIENCE platform is positioned to lead the digital transformation of life sciences in the age of personalized medicine with the first end-to-end scientific and business platform, from research to commercialization.

*Intel, 'AI and Wearables Bring New Data and Analytics to Clinical Trials,' 2017.

Disclaimer

Dassault Systèmes SA published this content on 27 October 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 27 October 2020 17:09:07 UTC


© Publicnow 2020
All news about DASSAULT SYSTÈMES SE
11/26DASSAULT SYSTEMES : Announces the Acquisition of NuoDB, a Cloud-Native Distribut..
AQ
11/25DASSAULT SYSTEMES : to Acquire U.S.-Based NuoDB
DJ
11/25DASSAULT SYSTÈMES : Announces the Acquisition of NuoDB, a Cloud-Native Distribut..
BU
11/25DASSAULT SYSTEMES : Systèmes Announces the Acquisition of NuoDB, a Cloud-Native ..
GL
11/25DASSAULT SYSTEMES : Systèmes Announces the Acquisition of NuoDB, a Cloud-Native ..
AQ
11/20HEALTHVERITY : and Medidata Announce Strategic Partnership to Advance Real World..
PR
11/19DASSAULT SYSTEMES : A Digital Alliance for “Space” within GAIA-X
PU
11/18DASSAULT SYSTEMES : Updates Multi-year Growth Plan, Targets 2020-2024 Non-IFRS E..
AQ
11/17DASSAULT SYSTEMES : Sees Earnings Gains in Coming Years
DJ
11/17DASSAULT SYSTEMES : Systèmes Updates Multi-year Growth Plan, Targets 2020-2024 N..
GL
More news
Financials
Sales 2020 4 454 M 5 329 M 5 329 M
Net income 2020 498 M 596 M 596 M
Net Debt 2020 2 202 M 2 634 M 2 634 M
P/E ratio 2020 81,8x
Yield 2020 0,47%
Capitalization 40 488 M 48 407 M 48 436 M
EV / Sales 2020 9,58x
EV / Sales 2021 8,60x
Nbr of Employees 21 557
Free-Float 49,9%
Chart DASSAULT SYSTÈMES SE
Duration : Period :
Dassault Systèmes SE Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends DASSAULT SYSTÈMES SE
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 24
Average target price 157,55 €
Last Close Price 155,30 €
Spread / Highest target 16,5%
Spread / Average Target 1,45%
Spread / Lowest Target -29,2%
EPS Revisions
Managers
NameTitle
Bernard Charlès Vice Chairman & Chief Executive Officer
Dominique Florack President
Charles Edelstenne Chairman
Pascal Daloz Chief Operating & Financial Officer
Laurence Barthès Executive VP, Chief People & Information Officer
Sector and Competitors
1st jan.Capitalization (M$)
DASSAULT SYSTÈMES SE5.97%48 407
OKTA, INC.104.59%30 234
BEIJING KINGSOFT OFFICE SOFTWARE, INC.89.34%22 066
HUNDSUN TECHNOLOGIES INC.42.84%13 611
NUANCE COMMUNICATIONS, INC.140.44%12 088
PAYLOCITY HOLDING CORPORATION65.84%10 869